TRANSGENE: Last Patient Enrolled in the Phase 2 Trial with Transgene's TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)

information fournie par Boursorama •27/05/2019 à 17:45

Clinical Trial in Collaboration with Bristol-Myers Squibb
Trial has Enrolled Patients whose Tumor Expresses Low or Undetectable Levels of PD-L1
Results for the Primary Endpoint (ORR) Expected in Q4 2019

Strasbourg, France, May 27, 2019, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces that the last patient has been included in the Phase 2 trial evaluating TG4010 in combination with Opdivo® (nivolumab) and chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with low or no expression of PD-L1 by the tumor cells.
Transgene confirms that the study's primary endpoint (objective response rate - ORR) on a minimum of 35 evaluable patients will be reported in Q4 2019.

The Phase 2 clinical trial is exploring the tolerability and efficacy of the combination regimen of Transgene's TG4010, an investigational active immunotherapy against MUC1 tumor-associated antigen, with Bristol-Myers Squibb's immune checkpoint inhibitor, Opdivo® (nivolumab), which acts by overcoming immune suppression, and standard platinum doublet chemotherapy.

.../...